Voyager Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
VYGR Nasdaq 2836 www.voyagertherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Voyager Therapeutics, Inc.

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 - Jul 13th, 2026 6:01 am
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s? - Jul 13th, 2026 12:00 am
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money - Jul 2nd, 2026 7:33 am
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside - Jun 30th, 2026 10:34 am
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 - Jun 29th, 2026 6:01 am
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - Jun 11th, 2026 2:01 pm
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation - Jun 9th, 2026 4:39 am
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease - Jun 1st, 2026 6:00 am
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs - May 20th, 2026 6:35 am
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 - May 13th, 2026 4:01 am
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 3:55 pm
Voyager Reports First Quarter 2026 Financial and Operating Results - May 7th, 2026 2:01 pm
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease - Apr 27th, 2026 2:31 pm
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut - Mar 22nd, 2026 9:03 pm
Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline? - Mar 12th, 2026 4:06 pm
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates - Mar 9th, 2026 3:15 pm
Voyager Therapeutics: Q4 Earnings Snapshot - Mar 9th, 2026 2:22 pm
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - Mar 9th, 2026 2:01 pm
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028 - Mar 2nd, 2026 3:03 am
Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag Estimates - Feb 26th, 2026 7:55 am